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Available online 6 July 2016Aims: Enzyme replacement therapy (ERT) has been shown to be effective in the treatment of Anderson–Fabry
disease (AFD). However, there have thus far been few reports on the histological ﬁndings of the heart in cases
treated with ERT for more than 10 years. We had an opportunity to examine the heart of an AFD patient that
had received ERT for more than 10 years, as well as those of two other patients, by autopsy, and compare the
pathological ﬁndings.
Methods and results: Three AFD patients who had received ERT for different durations underwent autopsy.
Marked left ventricular hypertrophy was observed in all three cases. The myocardial ﬁbrosis of the patient that
had been administered ERT for more than 10 years was much slighter when compared with the remaining
two cases.We further observed signiﬁcant differences in globotriaosylceramide (Gb3) deposition andmitochon-
dria in the cytoplasm of myocytes by electron microscopy.
Conclusion: ERT may not reduce left ventricular hypertrophy in AFD, but does prevent myocardial ﬁbrosis when
initiated before progression of ﬁbrotic change.




Enzyme replacement therapy1. Introduction
Anderson–Fabry disease (AFD) is a lysosomal storage disease caused
by mutations in the enzyme α-galactosidase A (α-GalA) gene located
on the X-chromosome. AFD causes inappropriate accumulation of
globotriaosylceramide (Gb3) and other sphingolipids within various
cell types throughout the body [1,2]. Major manifestations of AFD are
cardiac, renal, and neurological in nature. A typical cardiac manifesta-
tion is left ventricular (LV) hypertrophy with an end-diastolic wall
thickness of up to 16 mmwithout obstruction [3].
Currently, the key treatment for AFD is enzyme replacement therapy
(ERT)with recombinantα-GalA. Clinical short-term follow-up studies in
relatively small cohorts or registries have found that ERT leads to
regression of LV hypertrophy as well as an improvement in myocardial
function [4–6]. It has further been reported that ERT clearsmicrovascular
deposits of Gb3 where biopsies of the kidney, skin, and heart have been
performed [1,7]. Nevertheless, there have been few detailed reports. Nagano).
land Ltd. This is an open access articlregarding the histological ﬁndings of the heart following treatment
with ERT for more than 10 years.
Here we present a detailed examination of three whole hearts from
AFD patients that had received either long-term ERT for more than
10 years, short-term ERT for two years, or no ERT at all.
2. Materials and methods
2.1. Patients
Three patients with AFD were admitted to the National Cerebral and
Cardiovascular Centre, Japan; between September 1999, and February
2005. AFD diagnosis was based on a low level of plasmaα-Gal A activity,
the presence of LV hypertrophy, and electron microscopic observations
of endomyocardial biopsy specimens. Autopsies were performed on
these patients at three institutions betweenMay 2001, and January 2015.
2.2. Light microscopy
On autopsy, the heart and other organs were excised and ﬁxed in
10% buffered formalin. A transverse 1 cm thick slice was taken frome under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical and morphological characteristics of the three patients.
Case No. 1 2 3
Age at death 47 77 58
Plasma α-Gal A activity (nmol/h/ml)a) 2.6 1.3 1.4
Cerebrovascular damage (+) (−) (−)
Angiokeratoma (+) (−) (−)
Acroparesthesias (+) (−) (−)
Chronic renal failure (+) (−) (+)
Hemodialysis (+) (−) (−)
Ventricular arrythmia (+) (−) (−)
Duration of ERT (years) 13 2 none
Type of enzyme α→ β β none





Heart weight (g) 640 585 530
Fibrosis (+) (+++) (+++)
LVPW thickness (mm)b) 21 10 12
IVS thickness (mm)c) 17 20 13
Gb3 deposition to heart (++) (+++) (+++)
Gb3 deposition to kidney (+) (+) (+)
a Values in normal subjects ranged from 4.8 to 17.6 nmol/h/ml.
b LVPW means left ventricular posterior wall.
c IVS means interventricular septum.
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apex of the ventricle. Thismidventricular slice included the right ventri-
cle; the interventricular septum; and the anterior, lateral, and posterior
walls of the left ventricle. The tissue was dehydrated and embedded in
parafﬁn wax for cutting. Sections were cut at 5 μm and stained with
haematoxylin & eosin (H&E) or Masson's trichrome.
2.3. Immunohistochemistry
Immunohistochemical examinations were performed on 5 μm thick
formalin-ﬁxed and parafﬁn-embedded tissue sections. All steps were
performed on a Ventana BenchMark GX system (Roche Diagnostics,
Basel, Switzerland) according to the manufacturer's instructions. In
brief, specimens were deparafﬁnized and antigens were retrieved using
the instrument. All slides were incubated ﬁrst with primary antibodies
against Gb3 (dilution 1:1000; A2506, Tokyo Chemical Industry, Tokyo,
Japan), followed by a mouse-rabbit- horseradish peroxidase polymer
and 3,3′-diaminobenzidine substrate, after which sections were further
incubated with an anti-mouse primer. Antibody binding was visualized
using the avidin-biotin complexmethod according to themanufacturer's
instructions (Vectastain ABC; Vector, California, USA).
2.4. Electron microscopy
For electron microscopy, specimens were immersed in a ﬁxative
containing 3% glutaraldehyde and 2% paraformaldehyde buffered with
a 0.1 M phosphate buffer (pH 7.4). Specimens were post-ﬁxed with
osmium tetroxide, dehydrated in a graded series of ethanol baths, and
embedded in epoxy resin. Ultrathin sections were cut, double-stained
with uranyl acetate and lead citrate, and examined with an electron
microscope (model H-7100, Hitachi, Tokyo, Japan).
2.5. Statistical analysis
On the Masson's trichrome stained slides, all myocardial specimens
were arbitrarily divided into three zones corresponding with the
subepicardium, mesocardium, and subendocardium. In cases where
the specimen represented a sample of interventricular septum, this
too was divided into three zones; two of which were made up of
subendocardium on either side and one zone of mesocardium. To
evaluate tissue ﬁbrosis, the percentage area fraction was measured
using ImageJ software (version 1.48v; National Institutes of Health).
Images obtained using electron microscopy were evaluated for
intracellular structures such asmitochondria, Gb3 deposition, andmyo-
ﬁbrils; bymeasuring the percentage area fraction with ImageJ software.
These quantitative analyses were performed by two technicians
with no knowledge of the patients' backgrounds. Results are expressed
as the mean ± standard deviation (SD). All statistical analyses were
performed with EZR (Saitama Medical Centre, Jichi Medical University,
Saitama, Japan), a graphical user interface for R (The R Foundation for
Statistical Computing, Vienna, Austria) and a modiﬁed version of R
commander that is designed to add statistical functions frequently
used in biostatistics. Differences at speciﬁc stages between groups
were assessed using one-factor ANOVA and the Tukey test. A P-value
b0.05 was considered statistically signiﬁcant.
3. Results
3.1. Clinical and morphological data (Table 1)
Case 1. This patient had symptoms of acroparesthesias and
hypohydrosis and a history of angiokeratoma from childhood. He was
diagnosed with AFD at 19 years of age. The gene mutation data are
unknown. In May 2001, at the age of 34, this patient began treatment
with agalsidase-alpha (Replagal) at a dose of 0.2 mg/kg every 14 days.Renal failure had already developed by the time ERT was started since
the urinalysis showed a proteinuria level of 3+. His serum creatinine
level increased from 1.1 to 8.4 mg/dL after 3 years of ERT, and he had
been undergoing haemodialysis since the age of 37. At the age of 45,
this patient experienced an episode of cardiopulmonary arrest due to
ventricular ﬁbrillation and an implantable cardioverter deﬁbrillator
(ICD) was placed. At the age of 46, he had an infarct in the left occipital
lobe of the cerebrum. Since these events suggested a poor response to
ERT, the type of agalsidase was changed from alpha to beta (Replagal
to Fabrazyme) 2 months prior to the patient's death. The patient died
from cardiac failure and pneumonia in January 2015, 14 years after
replacement therapy.
Case 2. This patient was diagnosed with hypertrophic cardiomyopathy
in 1983 at the age of 53. When he was 62 years old, his brother was
diagnosed with AFD. Since he was suspected to have AFD cardiomyop-
athy, a myocardial biopsy was performed and AFD was subsequently
diagnosed at the age of 72. He refused to undergo the gene mutation
analysis. ERT of agalsidase-beta (Fabrazyme) was initiated in February
2005, at a dose of 1.0 mg/kg every 14 days. This patient died from
cardiac failure and pneumonia in December 2007, after 2 years of ERT.
The autopsy revealed Gb3 deposition not only in the myocytes, but
also in the epithelial cells of the proximal convoluted tubules of the
kidney.
Case 3. This patientwas treated for hypertrophic cardiomyopathy from
the age of 47. At the age of 51, he experienced an episode of syncope
from sinoatrial block and aDDI pacemakerwas implanted. Amyocardial
biopsy was performed and AFD was subsequently diagnosed. The gene
mutation data are unknown. This patient died from chronic heart failure
and chronic renal failure in 2001, 8 years after diagnosis. As ERTwas not
yet approved at that stage, the patient did not receive this treatment
prior to his death. Gb3 deposition in the myocytes and epithelial cells
of the glomeruli and proximal convoluted tubules of the kidney were
identiﬁed at autopsy.
For each patient, theweight of the heart was recorded as 640 g (Case
1), 585 g (Case 2) and 530 g (Case 3). In each case, the thickness of the
septal wall wasmeasured as 17mm, 20mmand 13mm, respectively. In
Case 1, the heart showed concentric LV hypertrophy and scant macro-
scopic ﬁbrosis area. In Cases 2 and 3, thinning and ﬁbrosis of the LV
wall were observed, especially in the lateral and posterior walls (Fig.
1A–C).
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In all three hearts, almost all myocytes throughout both ventricles
and atria showedmarked vacuolization (Fig. 1D–F). Immunohistochem-
ical study for Gb3 stained positively for these vacuoles (Fig. 1G–I). This
vacuolization was also observed in the medial smooth muscle cells of
the coronary and intramural arteries in all three cases. Interstitial ﬁbrosis
was found throughout the right and left ventricles, particularly in the lat-
eral and posterior walls of the left ventricle in Cases 2 and 3 (Fig. 2A–C).
3.3. Electron microscopy
In all three cases, electron microscopy showed typical lamellar and
whorled bodies within all myocytes (Fig. 3A–C). Intracellular structures
were carefully observed and themitochondria in themyocytes in Case 1
were found to be almost reserved, while the total area of themitochon-
dria in the cytoplasm was decreased in Cases 2 and 3, and the cristae
were coarse. Gb3 deposition was also higher in Cases 2 and 3 when
compared with Case 1. We could not deﬁne any quantitative difference
concerning the myoﬁbrils (Fig. 3D).
4. Discussion
Anderson-Fabry disease (AFD) is a multi-organ X-linked lysosomal
storage disease that primarily affects theheart, kidneys, and cerebrovas-
cular system. There have been many reports regarding the clinical
manifestations of AFD and more than 600 types of α-GalA geneFig. 1. (A–C)Macroscopicﬁndings of thehearts fromCases 1–3. (D–F) H&E staining of thehearts
of the hearts from Cases 1–3 (original magnitude ×200).abnormalities have been previously published [8]. However, the mech-
anismof Gb3deposition and resultant tissue dysfunction is not yet clear.
The α-GalA knockout mouse has been developed; however, this model
lacks the clinical symptoms observed in humans. Yet, no appropriate
animal model exists and we are dependent on the analysis of limited
clinical data and cultured cells, which presents a challenge in fully
understanding the pathophysiology of AFD.
Currently, the key treatment for this disease is enzyme replacement
therapy (ERT) with agalsidase beta (Fabrazyme(R), Genzyme Corpora-
tion, Cambridge, MA, USA) or agalsidase alfa (Replagal(R), Shire
Human Genetic Therapies AB, Lund, Sweden). Clinical short-term
follow-up studies in relatively small AFD cohorts or registries have
shown that ERT leads to a regression of LV hypertrophy and an improve-
ment inmyocardial function [4–6]. It has previously been demonstrated
in a double-blind, placebo-controlled study that ERT clears microvascu-
lar endothelial deposits of Gb3 from the kidneys, heart, and skin [1]. In
the present study, the hearts in Cases 1 and 2, which were treated
with ERT, showed minimal Gb3 deposits in microvascular endothelial
cells, as has been previously reported elsewhere [9].
In this study, marked LV hypertrophy was observed in all three
cases, although there was some variation in ﬁbrosis. In Case 1
(treated with long-term ERT), there was slight macroscopic ﬁbrosis
in the heart, which could be reﬂective of the efﬁcacy of ERT. The
ﬁbrosis observed in Case 2 did not differ signiﬁcantly from that of
Case 3 (no ERT). This is most likely attributable to the fact that ﬁbrot-
ic change in the heart had already progressed in Case 2, prior to ini-
tiation of ERT.fromCases 1–3 (originalmagnitude×100). (G–H) Immunohistochemical stainings toGb3
Fig. 2. (A, B)Masson-trichrome stainings of the hearts fromCases 1 and 3. (C) Fibrotic area of the threemyocardium layers of the anteroirwall (AW), lateralwall (LW), posteriorwall (PW)
of the left ventricle, interventricle septum (IVS) and the right ventricle (RV). ⁎shows signiﬁcant difference to Case 1 (p b 0.05).
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an end-diastolic wall thickness of up to 16 mm without obstruction
[3], as well as development of replacement ﬁbrosis in the basal
postero-lateral segments [10–12]. The presence of a growth-
promoting factor, which stimulates the proliferation of cardiomyocyte,
is speculated to play a role in the progression of LV hypertrophy [13].
The plasma level of globotriaosylsphingosine (lyso-Gb3), a deacylated
metabolite of Gb3, has been reported to be correlatedwith LV hypertro-
phy andmay therefore play a role in the progression of cardiac involve-
ment of AFD [13,14]. Another candidate for a cardiac tropic factor is
sphingosine-1-phosphate (S1P). The plasma level of S1P has been
shown to correlate with LVmass index, whilemice treatedwith S1P de-
velop cardiac hypertrophy [15]. Ischaemia, reactive oxygen species
(ROS), and pro-inﬂammatory cytokines including TGF β1 are all be-
lieved to be involved in the development ofﬁbrosis. In cultured vascular
endothelial cells, Gb3 accumulation has been reported to be associated
with increased ROS production [16]. Another study has shown that cul-
tured peripheral blood mononuclear cells (PBMC) from AFD patients –especially dendritic cells and monocytes – present with a higher pro-
inﬂammatory cytokine expression and production [17].
With regard to ischaemic changes in the cardiomyopathy of AFD,
there are few known deﬁnites. In the present study, no signiﬁcant
arteriosclerosis was observed in the coronal artery, even in Cases 2
and 3. A few cases of vasospastic angina in AFD patient were reported
[24,25]. Ischaemic change as a result of spasm of the coronal artery
could cause ﬁbrosis of the subendocardium layer of the LV; however,
the ﬁbrotic process is reported to start in the mesocardium layer before
spreading towards the transmural layer [18,19]. As we found slight ﬁ-
brosis in the perivascular area of the mesocardium layer in Case 1, it is
reasonable to speculate that microvascular dysfunction in this layer
could contribute to the development of ﬁbrosis. Microvascular dysfunc-
tion in AFD cardiomyopathywasdemonstrated by positron emission to-
mography, whichwas not altered by ERT [26,27]. It has been shown that
Lyso-Gb3 stimulates the proliferation of vascular smooth muscle cells
(SMC) in vitro [20]. Furthermore, S1P has been found to promote the
proliferation of vascular SMC in vitro, and the treatment of mice with
Fig. 3. (A–C) Electromicroscopic ﬁndings of the hearts from Cases 1–3. (D) Area of mitochondria, Gb3 deposition and myoﬁbril of the myocyte from Cases 1–3. (% to cytoplasm) ⁎shows
signiﬁcant difference to Case 1 (p b 0.05).
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expression is reduced in circulating angiogenic cells of AFD patients
in vitro [21]. Thus, it seems the interplay of increased vessel elasticity
and reduced NO-bioavailability in AFD patients could cause the micro-
vascular dysfunction observed in AFD cardiomyopathy (Fig. 4).Fig. 4.Hypothetical pathway that leads to ischaemia and ﬁbrosis in AFD cardiomyopathy.
Lyso-Gb3 denotes globotriaosylsphingosine, S1P sphingosine-1-phosphate, ROS reactive
oxygen species.Few studies on the investigation of electron microscopic details of
the cardiomyocytes of AFD patients have previously been reported. In
this study, we evaluated mitochondria, Gb3 deposition, and myoﬁbrils
using electron microscopy in all three cases. The percentage area of mi-
tochondria in the cytoplasm was signiﬁcantly reduced in Cases 2 and 3
when compared to Case 1 (6.5 ± 3.1, 7.6 ± 5.1 vs. 29.6 ± 10.3,
respectively; p = 0.01, 0.01), whereas Gb3 deposition was found to be
increased in Cases 2 and 3 when compared to Case 1 (23.9 ± 6.7,
23.6 ± 7.1 vs. 11.3 ± 4.5, respectively; p = 0.01, 0.02). The myoﬁbril
area too was reduced in Cases 2 and 3 when compared to Case 1, al-
though this was not statistically signiﬁcant (17.0 ± 4.5, 18.7 ± 5.7 vs.
22.7 ± 9.2, respectively; p = 0.26, 0.44).
The relationship between mitochondrial dysfunction and AFD car-
diomyopathy has not been clearly deﬁned, however, low levels of
high-energy phosphate molecules such as phosphocreatine and adeno-
sine triphosphate (ATP) have been observed in AFD [22]. It has further
been shown that the activity of mitochondrial respiratory chain
enzymes I, IV, and V is decreased in cultured AFD patient ﬁbroblasts
where ATP was marginally reduced [23]. These dysfunctions of cardiac
energy metabolism and increased oxygen requirements due to LV
hypertrophy may result in decreased ischaemic tolerance.
This study had several limitations, primarily the small sample size
and heterogeneity of the study population. Despite this, the observed
differences in ﬁbrotic area and intracellular structures such as mito-
chondria when comparing our patient who had undergone long-term
51T. Nagano et al. / IJC Metabolic & Endocrine 12 (2016) 46–51ERT with the remainder of the sample are indeed noteworthy. Future
studies are required to clearly deﬁne the precise pathophysiology in
AFD.
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